The legalization of psychedelics is an increasingly popular topic of discussion and public debate. Psychedelics are a group of chemicals that cause changes in perception, mood and consciousness. Many of these substances, such as LSD, psilocybin and DMT, were used traditionally in Native American and African cultures for spiritual and therapeutic purposes.
Since the 1960s. In the 1970s, psychedelics were banned worldwide due to their potential hallucinogenic effects and public health risks. More recently, however, a growing body of scientific research has shown that psychedelics can have beneficial therapeutic effects in the treatment of depression, anxiety and other mental disorders.
As a result, a debate is beginning on the legalization of psychedelics for therapeutic and spiritual purposes. In some countries, such as Canada and Portugal, psychedelics are already partially legal, provided they are used as part of a controlled therapeutic program. In other countries, such as Germany, the Netherlands and the US, debates are underway about the possibility of legalizing psychedelics in the future.
Image by upklyak on Freepik
History of the legality of psychedelics
The story is full of change and uncertainty. Psychedelics such as LSD, mescaline and psilocybin were first discovered in the 1940s. They were developed in the 1970s and quickly became popular in scientific and cultural circles. In their early days, psychedelics were considered a valuable tool for exploring consciousness and seeking spiritual experiences.
Advertising
However, within a few years, the popularity of psychedelics grew beyond scientific circles and began to be used in the context of hippie culture and protest movements against the Vietnam War. In response, many countries, including the United States, decided to outlaw psychedelics in the 1960s. i 70. In the 1970s.
However, in recent years, many countries are reconsidering the legalization of psychedelics in response to new research that shows their potential therapeutic benefits in treating various mental disorders. In some countries, such as Canada and Portugal, psychedelics are already partially or fully legalized for medical and therapeutic purposes.
Despite this, psychedelics remain banned in many countries and are considered dangerous and destructive to society. Therefore, the debate over their legality and safety continues.
Outlawing psychedelics in the context of the Vietnam War
Psychedelics such as LSD, mescaline and psilocybin were widely used in the 1960s. It was developed in the 1970s as a tool for experimenting with consciousness and seeking spiritual experiences. At the same time, the Vietnam War was underway and making headline news. In response to concerns that psychedelics could be used irresponsibly and dangerously by the military, the US government decided to outlaw the substances in 1970.
The decision was part of a broader government crackdown on hippie culture, which was considered a threat to public order and traditional values. Psychedelics were associated with protests against the war and the “freedom” culture, which was considered a threat to the country’s stability and security. As a result, the government has decided to outlaw these substances and ban their production, sale and possession.
The outlawing of psychedelics has had serious consequences for culture and science. Many studies on the potential health and therapeutic benefits of these substances have been discontinued, and researchers have been forced to move their efforts to other countries or abandon them altogether. As a result, knowledge about psychedelics and their potential impact on human consciousness and health has been greatly reduced.
Legalization of psychedelics from the perspective of the pharmaceutical industry
The pharmaceutical industry is one of the major players in the debate over the legalization of psychedelics. Many pharmaceutical companies are skeptical due to several factors.
First, the pharmaceutical industry is based on developing and selling drugs that are patentable and generate steady income for the company. Psychedelics, unlike drugs, are not patentable and their availability as drugs may be limited. As a result, pharmaceutical companies do not see psychedelics as a source of recurring revenue and are therefore not interested in developing them.
Second, the pharmaceutical industry requires a high level of clinical trials and regulation to get drugs approved by regulatory agencies such as the FDA in the United States. Research on psychedelics is still in its early stages and requires further study to gain a full understanding of their effects and safety. As a result, pharmaceutical companies may be reluctant to invest in research on psychedelics because the approval process can be difficult and expensive.
Third, the pharmaceutical industry is often criticized for its business practices and influence on drug prices. The legalization of psychedelics as drugs can be seen as a step toward allowing the availability of cheaper and more natural therapeutic options, which could reduce profits for the pharmaceutical industry.
In conclusion, many pharmaceutical companies are reluctant to legalize psychedelics due to concerns about the lack of recurring revenue
